Print

Frequently Asked Questions

What is the DermoDyneR PhotovaccinationR?

DermoDyneR is an innovative UV-free phototherapy, which is used primarily to treat chronic inflammatory skin diseases, such as psoriasis and atopic eczema. The wavelengths used are in the visible, predominantly blue light region. By use of a proprietary laser-like technology only specific, UV-free wavelengths are generated. The light penetrates through the upper skin to the dermis and then modulates the local immune cells. This induces a very long-term improvement and remission of atopic eczema and psoriasis,which could not be achieved by topical or systemic anti-inflammatory medication.

What is the mode of Action of the DermoDyneR PhotovaccinationR?

According to current opinion, the light rays react with skin's own breakdown products of red blood cells, known as porphyrins.The concentration of these porphyrins is increased in inflammatory cells activated by up to 500%. The intensive blue light leads to the death of these red stained inflammatory cells, while all other cells that have accumulated no porphyrin are not affected by irradiation.The presentation of fragments of dead inflammatory cells by immune cells of the skin - so-called antigen presenting cells - induces a regulatory processes, which is directed against inflammatory cells that are critical to the disease process, eg eczema or psoriasis - in analogy to allergy vaccination (desensitisation) against allergic rhinitis. The UV-free DermoDyneR light spares very sensitive immune cells that are destroyed by UV-radiation, sunlight, hot showers or topical cortisone. This is one of the reasons why we recommend the use of DermoDyneR LichtimpfungR for all infants aged from a few months.

What are the advantages of DermoDyneR PhotovaccinationR?

To illustrate the advantages of DermoDyneR therapy, first the side effects and risks of conventional therapies for atopic dermatitis and psoriasis are addressed.

Depending on the potency of the topical corticosteroid preparation there is a measurable and sometimes visible thinning of the upper skin layer within a few weeks. This so-called atrophy is initially completely reversible and normalizes the skin thickness after discontinuation of cortisone. For long-term and regular use of potent corticosteroids, it may cause permanent thinning of the treated skin, which is then often associated with increased sensitivity and vulnerability of the affected skin.

In addition recent results show an association between lymphoma-especially skin lymphoma-and use of topical corticosteroids. This cancer risk is increased with duration of exposure and potency of the prescriebed topical corticosteroids.

The latest generation of anti-inflammatory prescription drugs that are used for topical treatment of atopic dermatitis were initially used only internally in transplant patients to prevent organ rejection. The two are now available for external use drugs are tacrolimus (ProtopicR) and pimecrolimus (ElidelR). In transplant patients the long-term systemic immunosuppression often leads to various forms of skin cancer. Unfortunately use of topical tacrolimus has also recently been associated with an increased risk of T-cell lymphoma in patients with atopic eczema.

Serious side effects in biologics (TNF-alpha antagonists) for the treatment of psoriasis have been reported and the European Medicines Agency has recommended the suspension on 19/02/2009 the authorization of the TNF-alpha antagonists Raptiva (Efazulimab). The Authority is currently investigating about 30 cases of leukemia in children treated in Germany with these very expensive drugs.

What is the indication for the DermoDyneR PhotovaccinationR?

  • DermoDyneR therapy is helpful in steroid resistant
  • Atopic Eczema
  • Psoriasis (plaque and guttata)
  • Hand and foot Eczema
  • Acne vulgaris and other inflammatory skin diseases,

Use of DermoDyneR PhotovaccinationR?

Findings in recent years have shown that the effect of DermoDyneR is best if the treatment begins with the onset of acute relapse. In the event that no complete healing takes place the skin disease between attacks, it has proven very effective, after a brief - and therefore not risky - administration of topical corticosteroids (eczema usually for 2 days and psoriasis for 5 days) to achieve the greatest possible healing of the skin. If, after the discontinuation of topical corticosteroids a new exacerbation occurs, the DermoDyneR PhotovaccinationR is applied daily for 5 days (48 min irradiation time once or twice per day). This ensures that a fresh inflammatory infiltrate is irradiated, which presumably responds particularly well to the irradiation. If the skin remains stable, for example, after discontinuation of cortisone, the start of irradiation to be postponed until the actual onset of a relapse. Preventive radiation is not useful.

How many times should you be treated?

The number of treatments needed depends on the extent of the affected skin areas and the duration and severity of existing disease. According to clinical findings more or fewer treatments are required. In general, each treatment cycle consists of 5 treatments per week. Most patients experience a sustainable improvement after 3-4 cycles. In milder cases have been sufficient to 1-2 cycles to achieve sustainable improvements for one year or longer. In particularly severe cases – f.i. treated with cyclosporine - in some cases 10 or more cycles were necessary. So far, all patients could quit their cyclosporine treatment after DermoDyneR.

Can DermoDyneR also be performed in children?

Yes, especially for small children and infants, where traditional therapies are contraindicated the DermoDyneR therapy is probably the most promising therapeutic alternative. Experience has shown that children respond more quickly and to treatment, especially in critically ill infants. According to previous results, a 90% improvement can be achieved in many cases. DermoDyneR is not a cure, as the fundamental disposition of the skin persists, but a long term stabilization lasting months or even years can be achieved

Are there any side effects or contraindications?

According to current knowledge and treatment of over 4000 patients no adverse effects have been noticed.

As with any therapy there are certain DermoDyneR contraindications. These are very rare congenital photosensitive skin diseases (so-called porphyria). DermoDyneR irradiation principle is not recommended - due to insufficient experience - in HIV infection, active hepatitis, epilepsy or pregnancy.

At the same time no UV therapy, topical or systemic steroid medication should be applied or taken. Also, a desensitization, as it is carried out to treat hay fever should be completed prior to treatment. In acute (bacterial or influenza) infections, especially with fever DermoDyneR should be paused..

What should I consider when DermoDyneR PhotovaccinationR?

We ask that you keep your current medical treatment up to a first initial consultation. Depending on your symptoms you will receive a treatment recommendation to accompany the DermoDyneR PhotovaccinationR. In the DermoDyneR treatment centers specific diagnosistic procedures may be performed before initiation of DermoDyneR therapy. The course of therapy is reviewed regularly by a doctor. If possible, please bring written documentation on previous the medication and course of your disease.